Richard D. Peterson - 11 Dec 2021 Form 4 Insider Report for Clarus Therapeutics Holdings, Inc.

Reporting relationship: Chief Financial Officer
Issuer ticker: N/A
Reported as of: 11 Dec 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Dec 2021, 18:00:33 UTC
Prior SEC filing: 13 Sep 2021
Next SEC filing: 14 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Steven A. Bourne, attorney-in-fact

Key filing fact

Richard D. Peterson filed Form 4 for Clarus Therapeutics Holdings, Inc. on 14 Dec 2021.

Key facts

This page summarizes Richard D. Peterson's Form 4 filing for Clarus Therapeutics Holdings, Inc..
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 14 Dec 2021, 18:00.

Change

Previous filing in this sequence was filed on 13 Sep 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CRXT transaction

Common Stock

Award

Transaction value: $0
Shares: +55,800
Change %
Price: $0.000000
Shares after: 55,800
Date: 11 Dec 2021
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRXT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +139,500
Change %
Price: $0.000000
Shares after: 139,500
Date: 11 Dec 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 139,500
Exercise price: $4.78
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The Reporting Person was granted a Restricted Stock Unit under the Issuer's 2021 Stock Option and Incentive Plan (the "2021 Plan") for 55,800 shares on 12/11/2021, of which 25% vest on 9/9/2022, and the remaining shares vest in 36 equal monthly installments thereafter subject to the Reporting Person continuing to have a service relationship as of each such vesting date.

Footnote F2

These options were granted under the 2021 Plan and vest (i) 25% on 9/9/2022 and (ii) with the remainder vesting in 36 equal monthly installments thereafter subject to the Reporting Person continuing to have a service relationship as of each such vesting date.